RESPIRATORY SYNCYTIAL VIRUS INFECTION IN CHILDREN: ASSESSMENT OF SEVERE DISEASE RISK AND MODERN PREVENTION STRATEGIES

RESPIRATORY SYNCYTIAL VIRUS INFECTION IN CHILDREN: ASSESSMENT OF SEVERE DISEASE RISK AND MODERN PREVENTION STRATEGIES

Authors

  • G‘aybullayeva Asila Shokirjon qizi Tashkent International University of Kimyo, Namangan Branch (KIUT), Faculty of Pediatrics, 2nd-year student,
  • Kamalova Gulnora Gulyamovna PhD, Acting Assoc. Prof., Tashkent International University of Kimyo, Namangan Branch, Namangan, Uzbekistan

Keywords:

Respiratory syncytial virus, children, infants, bronchiolitis, severe respiratory infection, risk stratification, prematurity, respiratory failure, maternal vaccination, monoclonal antibodies, nirsevimab, clesrovimab, passive immunization, prevention, pediatric surveillance.

Abstract

Alcohol consumption during pregnancy remains an important and preventable risk factor for adverse fetal outcomes, including impaired intrauterine growth, congenital abnormalities, neurodevelopmental disturbances, and fetal alcohol spectrum disorders (FASD). Ethanol readily crosses the placental barrier, exposing the developing fetus to a substance that its immature metabolic systems cannot process as efficiently as those of an adult. The consequences of prenatal alcohol exposure vary according to the amount and pattern of consumption, timing and duration of exposure, maternal nutritional status, genetic susceptibility, placental function, and other environmental influences. This article aims to examine the principal biological mechanisms underlying alcohol-related fetal injury, summarize its clinical consequences, and identify evidence-based approaches to prevention and early recognition. A narrative review of international scientific publications, clinical guidance, and an official Uzbek antenatal-care document was undertaken. The literature was examined with particular attention to placental dysfunction, oxidative stress, cellular injury, altered gene regulation, impaired brain development, and disturbances in fetal growth. The findings of the reviewed literature indicate that prenatal alcohol exposure may interfere with neural cell proliferation, migration, differentiation, synaptic organization, and the development of essential organ systems. Clinically, the effects range from pregnancy loss and premature birth to growth restriction, characteristic facial differences in some affected children, congenital abnormalities, and persistent difficulties involving cognition, learning, attention, memory, and behavioral regulation. FASD represents a spectrum of conditions, and affected children do not necessarily exhibit the same physical characteristics or degree of impairment. The absence of obvious abnormalities at birth therefore does not exclude later neurodevelopmental difficulties. The review also highlights the importance of non-stigmatizing antenatal screening, clear communication about alcohol-related risks, and timely referral for appropriate support when alcohol use is difficult to discontinue. Current evidence does not establish a safe amount, type, or period of alcohol consumption during pregnancy. Complete abstinence while planning pregnancy and throughout gestation is consequently the most reliable preventive approach. Integrating preventive counseling into routine antenatal care, strengthening professional education, and improving developmental surveillance may reduce preventable harm and support affected children and their families.

References

World Health Organization. WHO position paper on immunization to protect infants against respiratory syncytial virus disease, May 2025. Weekly Epidemiological Record. 2025;100(22):193–218. Geneva: World Health Organization.

2. World Health Organization. Respiratory Syncytial Virus (RSV) Immunization Products. Geneva: World Health Organization; 2025. Online technical guidance, unpaginated.

3. Shi T., McAllister D.A., O’Brien K.L., et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. The Lancet. 2017;390(10098):946–958. Elsevier.

4. Yusupova G.A., Israilova N.A. Clinical and laboratory features of respiratory syncytial viral infection in young children. Medical Science of Uzbekistan / O‘zbekiston tibbiyot ilmi. 2025;4(2):48–50. Andijan State Medical Institute. DOI: 10.56121/2181-3612-2025-2-48-50.

5. Babadjanova F.R., Zaidova D.M. The global burden of respiratory syncytial virus infection in children: achievements and challenges of modern pediatrics. Medical Science of Uzbekistan / O‘zbekiston tibbiyot ilmi. 2025;4(6):143–147. Andijan State Medical Institute.

6. Centers for Disease Control and Prevention. Clinical Overview of RSV. Atlanta, GA: U.S. Department of Health and Human Services; 2025. Online clinical guidance, unpaginated.

7. Hammitt L.L., Dagan R., Yuan Y., et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. The New England Journal of Medicine. 2022;386(9):837–846. Massachusetts Medical Society.

8. Drysdale S.B., Cathie K., Flamein F., et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. The New England Journal of Medicine. 2023;389(26):2425–2435. Massachusetts Medical Society.

9. Kampmann B., Madhi S.A., Munjal I., et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. The New England Journal of Medicine. 2023;388(16):1451–1464. Massachusetts Medical Society.

Downloads

Published

2026-10-25
Loading...